Modulation of Microglia M2 Polarization and Alleviation of Hippocampal Neuron Injury By MiR-106b-5p/RGMa in a Mouse Model of Status Epilepticus

Yu, Tao; Huo, Liang; Lei, Jie; Sun, Jingjing; Wang, Hua

doi:10.1007/s10753-022-01686-1

Cited by 11 publications

(4 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, elezanumab is being used to treat SCI in a phase 2 study. Moreover, it has been shown that RGMan is able to intervene in the MAPK signaling pathway and thus achieve the corresponding function 147 . Second, Riluzole was able to increase the level of p38 MAPK, as well as the level of BDNP, which is undoubtedly essential for neuronal survival and axonal regeneration.…”

Section: Clinical Trial For Sci Related To Mapk Signaling Pathwaymentioning

confidence: 99%

Advances of the MAPK pathway in the treatment of spinal cord injury

Huang,

Zhang,

Shu

et al. 2024

CNS Neurosci Ther

View full text Add to dashboard Cite

Spinal cord injury (SCI) represents a complex pathology within the central nervous system (CNS), leading to severe sensory and motor impairments. It activates various signaling pathways, notably the mitogen‐activated protein kinase (MAPK) pathway. Present treatment approaches primarily focus on symptomatic relief, lacking efficacy in addressing the underlying pathophysiological mechanisms. Emerging research underscores the significance of the MAPK pathway in neuronal differentiation, growth, survival, axonal regeneration, and inflammatory responses post‐SCI. Modulating this pathway post‐injury has shown promise in attenuating inflammation, minimizing apoptosis, alleviating neuropathic pain, and fostering neural regeneration. Given its pivotal role, the MAPK pathway emerges as a potential therapeutic target in SCI management. This review synthesizes current knowledge on SCI pathology, delineates the MAPK pathway's characteristics, and explores its dual roles in SCI pathology and therapeutic interventions. Furthermore, it addresses the existing challenges in MAPK research in the context of SCI, proposing solutions to overcome these hurdles. Our aim is to offer a comprehensive reference for future research on the MAPK pathway and SCI, laying the groundwork for targeted therapeutic strategies.

show abstract

Section: Clinical Trial For Sci Related To Mapk Signaling Pathwaymentioning

confidence: 99%

Advances of the MAPK pathway in the treatment of spinal cord injury

Huang,

Zhang,

Shu

et al. 2024

CNS Neurosci Ther

View full text Add to dashboard Cite

show abstract

“…However, the relationship between the miR-106b profile and epilepsy is not well understood yet, and the effect of such miRNA expression on neurons is a subject for discussion [38,39]. In a pilocarpine-induced status epilepticus model in mice, inhibition of miR-106b-5p expression reduced the expression of the repulsive guidance molecule A (RGMa), resulting in M2 microglia polarization, reduced inflammatory response, and decreased neuronal damage [40,41]. An increase in the expression of circulating miR-106b in patient blood plasma was detected during and after an epileptic seizure in children with generalized forms of epilepsy [42], in adult patients with focal and generalized forms of epilepsy with a disease duration of over five years [43,44,45].…”

Section: Avansini Et Al (2017) On Mtle Patients With Hippocampal Scle...mentioning

confidence: 99%

MiR-134 And MiR-106b Are Circulating Biomarkers For Temporal Lobe Epilepsy: Pilot Study Results

Lysova,

Usoltseva,

Domoratskaya

et al. 2023

Russ Open Med J

View full text Add to dashboard Cite

Temporal lobe epilepsy (TLE) is among the most common forms of focal epilepsy in adults. Currently, scientists search for microRNAs as noninvasive epilepsy biomarkers. MicroRNAs constitute a class of short (or small) non-coding RNAs that control the level of gene expression affecting the stability of mRNA. They are key regulators and therapeutic targets in epilepsy. Considering the role of miRNA-134 and miRNA-106b in the processes of epileptogenesis, the goal of our study was the clinical evaluation of their circulation as novel noninvasive molecular diagnostic markers of TLE. Material and Methods — Our pilot study involved 59 participants. The main group included 33 patients with mesial temporal lobe epilepsy, the control group encompassed 26 healthy volunteers. The ranking of patients was carried out depending on the disease duration, presence of epileptiform activity on the electroencephalogram (EEG) and hippocampal sclerosis on MRI, the number of taken antiepileptic drugs (AEDs), and patient response to the pharmacotherapy of epilepsy. The isolation of circulating microRNAs from blood plasma was accomplished via the sorption method, and the analysis of microRNA expression was performed by real-time PCR. Results — The expression levels of miR-134 and miR-106b in blood plasma in patients with TLE were reduced. Therefore, these microRNAs can be diagnostic biomarkers of patients with TLE, compared with the control group. The results of receiver operating characteristic (ROC) analysis yielded high sensitivity and specificity values of this biomarker for the diagnosis of TLE. Conclusion — Circulating miR-134 and miR-106b concentrations were significantly reduced in patients with mesial TLE (MTLE), compared with healthy controls. At the same time, the level of microRNA expression did not depend on the presence of hippocampal sclerosis and the response to antiepileptic therapy.

show abstract

“…Furthermore, inhibition of miR106b-5P expression promotes M2 polarization of microglia and reduces inflammatory responses, thereby attenuating neuronal damage. Therapeutic strategies targeting this factor or related downstream factors may be effective in preventing and treating epileptogenesis (Yu, Huo et al 2022). The study on microRNAs and epilepsy has highlighted the significance of neuroinflammation as a research focus that will continue to be explored in future investigations; therefore, further research is warranted to elucidate the precise mechanism underlying the interaction between microRNAs and inflammation in epilepsy.…”

Section: Inflammationmentioning

confidence: 99%

MicroRNAs in epilepsy: a bibliometric study from 2007 to 2023

Ling,

Tong,

Tang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background and objective: MicroRNAs are a class of endogenous small non-coding single-stranded RNA molecules. It regulates gene expression at the post-transcriptional level by binding to one or more mRNA molecules that are partially complementary. microRNA has also been extensively studied in epilepsy. This study aimed to evaluate the current status of microRNA research in epilepsy and to identify research hotspots and trends using bibliometric and visual analysis methods. Methods We used Scopus, the largest literature abstract and citation database, to search for literature that met the inclusion criteria. Citespace6.2. R 3, VOSviewer 1.6.17, Excel, and Scimago Graphica visualization and analysis tools were used to analyze countries, institutions, authors, journals, references, and keywords in the field. Results A total of 929 publications were included. There was a large number of publications and citations related to epilepsy and microRNAs. The International Journal of Molecular Sciences was the journal with the largest number of papers published on epilepsy and microRNAs, and the Royal College of Surgeons of Ireland was the issuing organization with the largest volume of papers. Through a comprehensive analysis of keywords and references, we identified the priorities and future research trends in epilepsy and microRNA. Conclusions We used bibliometric methods to describe the current research status of microRNA and epilepsy, and the main content and future research trends of epilepsy and microRNA, including the top three microRNAs, inflammation, oxidative stress, drug resistance-related proteins, blood-brain barrier function, neuroplasticity, exosome, lncRNA, other diseases, and biomarkers.

show abstract

Modulation of Microglia M2 Polarization and Alleviation of Hippocampal Neuron Injury By MiR-106b-5p/RGMa in a Mouse Model of Status Epilepticus

Cited by 11 publications

References 64 publications

Advances of the MAPK pathway in the treatment of spinal cord injury

Advances of the MAPK pathway in the treatment of spinal cord injury

MiR-134 And MiR-106b Are Circulating Biomarkers For Temporal Lobe Epilepsy: Pilot Study Results

MicroRNAs in epilepsy: a bibliometric study from 2007 to 2023

Contact Info

Product

Resources

About